Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Olema Pharmaceuticals (OLMA) Equity Average (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Equity Average data on record, last reported at $479.5 million in Q1 2026.

  • On a quarterly basis, Equity Average rose 21.03% to $479.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $479.5 million, a 21.03% increase, with the full-year FY2025 number at $443.8 million, up 33.89% from a year prior.
  • Equity Average reached $479.5 million in Q1 2026 per OLMA's latest filing, up from $393.0 million in the prior quarter.
  • Over the last five years, Equity Average for OLMA hit a ceiling of $479.5 million in Q1 2026 and a floor of $168.3 million in Q2 2023.
  • A 5-year average of $279.5 million and a median of $250.7 million in 2022 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: plummeted 32.87% in 2023, then soared 61.65% in 2025.
  • Tracing OLMA's Equity Average over 5 years: stood at $207.6 million in 2022, then grew by 27.4% to $264.5 million in 2023, then grew by 14.9% to $303.9 million in 2024, then increased by 29.31% to $393.0 million in 2025, then grew by 22.01% to $479.5 million in 2026.
  • Business Quant data shows Equity Average for OLMA at $479.5 million in Q1 2026, $393.0 million in Q4 2025, and $326.4 million in Q3 2025.